Pain by Keith Wailoo Page B

F1; for “competitors financial aches,” see Michael Millenson, “New Pain Relievers May Give Competitors Financial Aches,”
Chicago Tribune
, May 27, 1984, H1; for “an arrogant and unconscionable effort,” see Patti Domm, “Tylenol to Get Rival,”
Baltimore Sun
, May 28, 1984, D8.
    16 . Dale Gieringer, “The FDA Continues to Commit Regulatory Malpractice,”
Wall Street Journal
, March 27, 1985, 34.
    17 . For “a Federal grand jury …,” see Richard Wood, chair, Eli Lilly and Company, “Of Eli Lilly and the Short Life of Oraflex on the U.S. Market,”
New York Times
, October 12, 1985, 26; for Lola Jones and “we’re a little disappointed …,” see “Oraflex Death Brings Award of $6 Million,”
Los Angeles Times
, November 22, 1983, B5.
    18 . For “frivolous lawsuits,” see Caryle Murphy, “Eli Lilly Co. Cleared in Va. Death,”
Washington Post
, September 10, 1985, D6; for industry victory,
National Childhood Vaccine Injury Act of 1986, House Committee on Energy and Commerce
, report 99-908 part 1 (Washington D.C.: Government Printing Office, 1986).
    19 . For “threatened to transform …,” see George Annas, “Faith (Healing), Hope and Charity at the FDA: The Politics of AIDS Drug Trials,”
Villanova Law Review
34 (1989): 771–97; for “lurching from one crisis …” and “three FDA employees …,” see Bruce Ingersoll and Gregory Stricharchuk, “Generic-Drug Scandal at FDA Is Linked to Deregulation Drive,”
Wall Street Journal
, September 13, 1989, A1; see also Richard Berke, “Deregulation Has Gone Too Far, Many Tell the New Administration,”
New York Times
, December 11, 1988, 1.
    20 . Pilar Kraman,
Drug Abuse in America—Prescription Drug Diversion
(Washington, D.C.: Council of State Governments, 2004); for “one New Mexico …,” see Pete Stark, “Not All Drug Lords Are Outlaws,” Op-Ed,
New York Times
, August 12, 1990, E21.
    21 . For “prescription drug abuse …,” “how the legal distribution …,” and “a patient will present …,” see David Pesci, “Connecticut Q and A: William Ward, Ferreting Out Illegal Use of Legal Drugs,”
New York Times
, July 3, 1994, CN3; for “doctors who help …,” see Tim Golden, “Doctors Are Focus of Plan to Fight New Drug Laws,”
New York Times
, December 23, 1996, A10.
    22 . For changing advertising, see Lawrence K. Altman, “Prescription Drugs Are Advertised to Patients, Breaking with Tradition,”
New York Times
, February 23, 1982, C1; for AMA concerns, see Michael Millenson, “New Pain Drug Ordered Too Readily, Group Says,”
Chicago Tribune
, March 7, 1983, 3.
    23 . Elisabeth Rosenthal, “Maybe You’re Sick. Maybe We Can Help,”
New York Times
, April 10, 1994, E2; for “a major concern …,” see Louis A. Morris and Lloyd G. Millstein, “Drug Advertising to Consumers: Effects of Formats for Magazine and Television Advertisements,”
Food Drug Cosmetics Law Journal
39 (1984): 497–503; see also Louis A. Morris et al., “Miscomprehension Rates for Prescription Drug Advertisements,”
Current Issues and Research in Advertising
9 (1986): 1, 93–117; for other manufacturer concerns, see Mary Jane Sheffet and Steven W. Kopp, “Advertising Prescription Drugs to the Public: Headache or Relief?”
Journal of Public Policy and Marketing
9 (1990): 42–61; for “increasing price competition …,” see Richard B. Schmitt, “Prescription Drug Ads Stir New Wave of Court Battles,”
Wall Street Journal
, October 4, 1994, B10. As this article noted, “In mid-August [1994], for example, a federal judge in Hartford, Conn., ordered Pfizer, Inc., to overhaul a campaign that criticized a new hypertension drug developed by the Miles unit of Bayer AG. The Miles drug,